Drug Trial Radar · NCT01599286
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Last checked: Nov 20, 2026Latest source record: Feb 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Sep 1, 2012
Primary completion
Apr 30, 2019
Study completion Apr 30, 2020
Sponsor
- Lead sponsor
- Mendel TuchmanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Children's National Research Institute; Boston Children's Hospital; University Hospitals Cleveland Medical Center; University of California, Los Angeles; Children's Hospital of Philadelphia; Stanford University; Icahn School of Medicine at Mount Sinai; University of Pittsburgh; Children's Hospital Colorado
- First posted
- May 16, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 week, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this drug trial is to determine whether the treatment of acute hyperammonemia with N-carbamyl-L-glutamate (NCG, Carglumic acid) in propionic acidemia (PA), methylmalonic acidemia (MMA), late-onset CPS1 deficiency (CPSD) and late-onset Ornithine transcarbamylase deficiency (OTCD) accelerates the resolution of hyperammonemia efficiently and safely. The primary goal is to determine if the study drug (NCG) efficiently reduces ammonia levels following a hyperammonemia episode(s). Secondly, the investigators want to know if treatment with this study drug (NCG) efficiently improves neurologic function, reduces plasma glutamine levels and lessens the duration of hospitalization after each episode of hyperammonemia.
Conditions
- Propionic Acidemia, Type I and/or Type II
- Methylmalonic Acidemia
- Carbamoyl-Phosphate Synthase I Deficiency Disease
- Ornithine Carbamoyltransferase Deficiency
Interventions
CarbagluDrug
Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG) The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients \>15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration. The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.
PlaceboDrug
Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the Primary Outcome (Earlier of Ammonia <50 µmol/L or Hospital Discharge)Time frame: Average of all measurements of hyperammonemia, for up to 7 days
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
Lucile Packard Children's Hospital at Stanford
Palo Alto, California
The Children's Hospital of Colorado
Aurora, Colorado
Children's National Medical Center
Washington D.C., District of Columbia
Children's Hospital Boston
Boston, Massachusetts
Mount Sinai School of Medicine
New York, New York
University Hospitals Cleveland Medical Center
Cleveland, Ohio
The Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.